

RECEIVED

12. (Once Amended) The composition of claim 8 wherein said composition is in a granule or pellet form.

TECH CENTER 1600/2900



REMARKS

Applicants have corrected the informalities in Claims 1 and 10-12, as noted by the Examiner. A marked up version of amended Claims 1 and 10-12 is provided in the attached Appendix.

The Examiner has rejected Claims 1 and 8-20 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-8 of U.S. Patent No. 6,172,107. In addition, the Examiner has rejected Claims 1 and 8-20 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-11 of USP 6,025,391.

In response, Applicants has included herewith a Terminal Disclaimer. A copy is attached for review by the Examiner.

Applicants respectfully request that the Examiner enter applicants' amendment, remove all rejections and pass the application to issuance.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6950

John D. Thallemer
John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Date: MAY 17 2001

B